Viron is developing a next-generation antiviral technology, with its first product, Viron C1, currently under FDA review as a prophylactic against COVID-19. The company utilizes a proprietary porosome platform to address secretory defects in various diseases, including cystic fibrosis and diabetes, by reconstituting functional porosome machinery into affected cells to restore normal cellular function.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including cystic fibrosis, diabetes, Alzheimer's disease, and various cancers, result from secretory defects in porosomes, the cellular structures responsible for intercellular communication. A significant portion of the human proteome is considered "undruggable" using traditional methods, limiting therapeutic options for these diseases. Current treatments often fail to address the underlying secretory defects or have limited efficacy due to the inability to target specific disease-causing proteins within the porosome.
Solution
Porosome Therapeutics is developing a platform to address secretory defects by targeting the porosome. The company's approach involves reconstituting functional porosome machinery into diseased cells or precision-targeting specific proteins within the porosome using small molecules and nanobodies. This enables the modulation of secretory functions and the development of therapies for previously "undruggable" targets. The platform facilitates the identification of novel high-affinity pockets within target proteins and the creation of innovative covalent small molecules that engage crucial drug targets.
Target Audience
The primary target audience includes patients suffering from diseases caused by secretory defects, such as cystic fibrosis, diabetes, Alzheimer's disease, lung adenocarcinoma, and other conditions with limited therapeutic options, as well as researchers and clinicians in these fields.
Features
- Functional reconstitution of the porosome complex in lipid membranes and live cells
- Tissue-specific porosome-targeted therapy for a wide range of medical conditions
- Nanobody-assisted drug delivery for precision medicine
- Small molecule drugs and nanobodies targeting the porosome proteome in lung epithelial cells for lung adenocarcinoma
- Mesenchymal stem cell secretion-based therapy for myopathies
- Reconstitution of functional insulin-secreting porosomes into iPSC-derived β cells for Type 1 Diabetes
- Small molecule therapies designed to restore insulin-secreting capabilities of diseased β-cells for Type 1 and Type 2 Diabetes
- AI-driven analysis to reveal how beta-amyloid disrupts key protein interactions within the neuronal secretory machinery for Alzheimer's disease